A NEW ERA OF VACCINES

Latest press release on vaccine candidates

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

2 billion

doses per year
at full capacity

10+ years

of nanoparticle
vaccine development

1,500+

employees
worldwide

6

areas of
research

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that
NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Novavax first quarter 2022 financial results

Browse the calendar and sign up to view investor-related events and announcements. Webcasts and presentations that have been archived are also available by viewing historical event details.

Latest quarterly earnings
Latest investor presentation
2021 annual report
NASDAQ:NVAX
Loading data...

Explore current opportunities in:

Leslie Harrison

I’m most inspired by our global impact.
Together, we can help improve the lives of people around the world.

Leslie Harrison
Senior HR Information Systems Specialist

Insights

Why do we need vaccine booster injections?

Science & technology

Our pipeline—creating tomorrow's vaccines today

Who we are

Novavax is powered by global collaborations